| Cost-effectiveness of rivaroxaban after total hip or total knee arthroplasty. | |
| | |
MedLine Citation:
|
PMID: 21517652 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
Venous thromboembolism (VTE) following joint replacement surgery represents an economic as well as a clinical burden; however, the risk of thromboembolic events is greatly reduced by appropriate anticoagulation. Rivaroxaban, a Factor Xa inhibitor currently in phase III development, was compared with the low molecular weight heparin enoxaparin in 4 clinical trials, collectively called the RECORD program (REgulation of Coagulation in Orthopedic Surgery to Prevent Deep Venous Thrombosis and Pulmonary Embolism). In a pooled analysis of data from the RECORD trials, rivaroxaban was superior to enoxaparin regimens in reducing the composite end point of symptomatic venous thromboembolism and all-cause mortality in patients following elective primary total hip or total knee arthroplasty (THA or TKA), with a comparable incidence of major bleeding events. In cost-effectiveness analyses, compared with enoxaparin, rivaroxaban showed the potential to reduce costs associated with the prophylaxis and treatment of thromboembolic events in a post-orthopedic surgery/arthroplasty population. |
| | |
Authors:
|
Louis M Kwong |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: The American journal of managed care Volume: 17 ISSN: 1936-2692 ISO Abbreviation: Am J Manag Care Publication Date: 2011 Feb |
Date Detail:
|
Created Date: 2011-04-26 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9613960 Medline TA: Am J Manag Care Country: United States |
Other Details:
|
Languages: eng Pagination: S22-6 Citation Subset: H |
Affiliation:
|
Department of Orthopaedic Surgery, Harbor-UCLA Medical Center, Torrance, CA 90509, USA. lmkwongmd@hotmail.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: New oral anticoagulants and outpatient prophylaxis of venous thromboembolism.
Next Document: Characteristics of novel anticoagulants and potential economic implications.